These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 20539104)

  • 21. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
    Bensen WG
    J Rheumatol Suppl; 2000 Oct; 60():17-24. PubMed ID: 11032098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    Borer JS; Simon LS
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Strand V
    Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases].
    Jukić A; Kaliterna DM; Radić M
    Reumatizam; 2010; 57(1):26-8. PubMed ID: 20941937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance.
    Hohlfeld T; Saxena A; Schrör K
    Thromb Haemost; 2013 May; 109(5):825-33. PubMed ID: 23238666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
    Konstantinopoulos PA; Lehmann DF
    J Clin Pharmacol; 2005 Jul; 45(7):742-50. PubMed ID: 15951464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events.
    Mitchell JA; Lucas R; Vojnovic I; Hasan K; Pepper JR; Warner TD
    FASEB J; 2006 Dec; 20(14):2468-75. PubMed ID: 17142796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
    Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
    Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials.
    Scott PA; Kingsley GH; Scott DL
    Eur J Heart Fail; 2008 Nov; 10(11):1102-7. PubMed ID: 18760966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prescription of NSAIDs in patients treatment with platelet inhibitors or anticoagulants].
    Avouac B; Combe B; Darné B
    Presse Med; 2003 Nov; 32(37 Pt 2):S38-43. PubMed ID: 14763353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential cardiovascular effects of COX-2 selective nonsteroidal antiinflammatory drugs.
    Fowles RE
    J Pain Palliat Care Pharmacother; 2003; 17(2):27-50. PubMed ID: 14649387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects].
    Batlouni M
    Arq Bras Cardiol; 2010 Apr; 94(4):556-63. PubMed ID: 20498929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy.
    Khan MN; Lee YS
    Med Res Rev; 2011 Mar; 31(2):161-201. PubMed ID: 19967720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.